作者：
Authier, Simon [1]
;
Abernathy, Matthew M. [2]
;
Correll, Krystle [3]
;
Chui, Ray W. [4]
;
Dalton, Jill A. [5]
;
Foley, Michael C. [6]
;
Friedrichs, Gregory S. [7]
;
Koerner, John E. [8]
;
Kallman, Mary Jeanne [9]
;
Pannirselvam, Malar [10]
;
Redfern, William S. [11]
;
Urmaliya, Vijay [12]
;
Valentin, Jean-Pierre [13]
;
Wisialowski, Todd [14]
;
Zabka, Tanja S. [15]
;
Pugsley, Michael K. [16]
作者单位：
Citoxlab, Laval, PQ, Canada
[1]
Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2]
Safety Pharmacol Soc Headquarters, Reston, VA USA
[3]
Amgen Inc, Thousand Oaks, CA USA
[4]
Charles River, Mattawan, MI USA
[5]
Abbvie, N Chicago, IL USA
[6]
Novartis, E Hanover, NJ USA
[7]
US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8]
Kallman Preclin Consulting, Greenfield, IN USA
[9]
Vertex, Cambridge, MA USA
[10]
Certara UK Ltd, Sheffield, S Yorkshire, England
[11]
Janssen Res & Dev, Beerse, Belgium
[12]
UCB Biopharma, Braine Lalleud, Belgium
[13]
Pfizer Inc, Groton, CT 06340 USA
[14]
Genentech Inc, San Francisco, CA USA
[15]
Cytokinet, San Francisco, CA USA
[16]
发布时间
2022-09-10
换一批
